Common endocrine system adverse events associated with immune checkpoint inhibitors  

作　　者：Ying Li Junfeng Zhao Yue Wang Yali Xu Ruyue Li Ying Zhao Xue Dong Xiujing Yao Yintao Li 

机构地区：[1]Department of Medical Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University,Shandong Academy of Medical Sciences,Jinan,Shandong 250000,China [2]Department of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University,Shandong Academy of Medical Sciences,Jinan,Shandong 250000,China [3]National Institutes for Food and Drug Control,Beijing 102629,China [4]Department of Pathology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan,Shandong 250000,China [5]Department of Medical Oncology,Shandong Cancer Hospital and Institute,Affiliated Hospital of Weifang Medical University,School of Clinical Medicine,Weifang Medical University,Weifang,Shandong 261000,China

出　　处：《Cancer Pathogenesis and Therapy》2024年第3期164-172,共9页癌症发生与治疗（英文）

基　　金：supported by the National Natural Science Foundation of China(No.82373044);the Natural Science Foundation of Shandong Province(No.ZR2022LSW001).

摘　　要：Immune checkpoint inhibitors(ICIs),a novel anti-tumor therapeutic modality,are monoclonal antibodies targeting certain immune checkpoints(ICs)that reactivate T cells to achieve anti-tumor immunity by targeting,binding,and blocking ICs.Targeted inhibitory antibodies against the ICs cytotoxic T-lymphocyte antigen and programmed death receptor-1 have demonstrated efficacy and durable anti-tumor activity in patients with cancer.ICs may prevent autoimmune reactions.However,ICIs may disrupt ICs properties and trigger autoimmune-related adverse reactions involving various organ systems including the cardiovascular,pulmonary,gastrointestinal,renal,musculoskeletal,dermal,and endocrine systems.Approximately 10%of patients with damage to target organs such as the thyroid,pituitary,pancreas,and adrenal glands develop endocrine system immune-related adverse events(irAEs)such as thyroid dysfunction,pituitary gland inflammation,diabetes mellitus,and primary adrenal insufficiency.However,the symptoms of immunotherapy-associated endocrine system irAEs may be nonspecific and similar to those of other treatment-related adverse reactions,and failure to recognize them early may lead to death.Timely detection and treatment of immunotherapy-associated endocrine irAEs is essential to improve the efficacy of immunotherapy,prognosis,and the quality of life of patients.This study aimed to review the mechanisms by which ICIs cause endocrine irAEs providing guidance for the development of appropriate management protocols.Here,we discuss(1)the biological mechanisms of ICs in tumorigenesis and progression,focusing on cytotoxic T-lymphocyte antigen and programmed cell death-1/programmed cell death-ligand 1;and(2)the epidemiology,clinical symptoms,diagnosis,and treatment of four immunotherapy-related endocrine complications.

关 键 词：Immune checkpoint inhibitors Immune checkpoints Cytotoxic T-lymphocyte antigen 4 Programmed cell death-1 Programmed cell death-ligand 1 Endocrine autoimmune-related adverse reactions 

分 类 号：R730.51[医药卫生—肿瘤]